

**Minutes of the June 11, 2010  
Pharmacy & Therapeutics (P&T) Committee Meeting  
SD Department of Social Services, Medical Services Division**

**Members present**

Dana Darger, R.Ph; Bill Ladwig, R.Ph; Rick Holm, M.D.; Debra Farver, PharmD.; Verdayne Brandenburg, M.D.; Willis Sutliff, M.D.; Galen Goeden, R.Ph; James Engelbrecht, M.D.

**Members absent**

Timothy Soundy, M.D.; Dennis Hedge, PharmD.

**DSS staff present**

Mike Jockheck, RPh.

**HID staff present**

Candace Rieth, Pharm.D.

**Administrative Business**

The P&T meeting was called to order by D. Darger at approximately 1:05pm. The minutes of the March 12, 2010 meeting were presented. B. Ladwig made a motion to approve. V. Brandenburg seconded the motion. The motion was approved unanimously. B. Ladwig made a motion to review all current medications on prior authorization (forms and criteria) annually. J. Engelbrecht seconded the motion. The motion was approved unanimously. W. Sutliff made a motion that information regarding patent expirations and pipeline medications be included in the quarterly P&T packet. D. Farver seconded the motion. The motion was approved unanimously.

**Prior Authorization Statistics**

C. Rieth presented an overview of the prior authorization (PA) activity for April 2010. There were a total of 1,912 PAs processed in the month of April, with 99.79% of those requests responded to in less than 8 hours. There were 1,648 (86%) requests received electronically and 264 (14%) requests received by fax. In response to a request from the committee, C. Rieth presented the number of approvals and denials, by form type, for the faxed (manual) PA requests.

**Analysis of the Top 15 Therapeutic Classes**

C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 01/01/2010 – 03/31/2010. The top five classes were antipsychotics, cerebral stimulants, amphetamines, beta-adrenergic agonists, and antidepressants. The top 15 therapeutic classes make up 44.70% of total claims.

**ADD/ADHD Review**

C. Rieth presented clinical information and data for medications used to treat ADD/ADHD. The committee suggested that a list of prescribers be included in the next review. The committee also requested step therapy information from other state Medicaid programs. Dr. Carroll Isburg spoke against prior authorization of medications used to treat ADD/ADHD. Dr. Jerry Blake spoke against prior authorization of medications used to treat ADD/ADHD. John Brokars, representing Lilly, discussed prescribing information for Strattera. Phyllis Arends, representing NAMI, spoke against prior authorization of medications used to treat ADD/ADHD. J. Engelbrecht made a motion to review this information at the next meeting. R. Holm seconded the motion. The motion was approved unanimously.

### **Suboxone/Subutex**

C. Rieth presented clinical information and data for Suboxone and Subutex. Dave Helgeland, representing SDSU College of Pharmacy and the RDUR committee, discussed certification of Suboxone/Subutex prescribers. G. Goeden made a motion to place Suboxone and Subutex on prior authorization. V. Brandenburg seconded the motion. The motion was approved unanimously.

### **Opiate Agonist Review**

C. Rieth presented clinical information and data for the opiate agonists. There was no public comment. A motion was made by B. Ladwig to further review opiate agonists including a list of products that are appropriate for prior authorization. W. Sutliff seconded the motion. The motion was approved unanimously.

### **High Cost/Low Utilization Drugs**

C. Rieth presented a table showing high cost/low utilization drug utilization for 2009. There was no public comment. J. Engelbrecht made a motion to review this topic further, including research on specialty pharmacies and their place in SD Medicaid. R. Holm seconded the motion. The motion was approved unanimously.

The next meeting date is scheduled for September 10, 2010. The location will be updated on the website as soon as possible. A motion was made by B. Ladwig at 3:05pm to adjourn the SD Medicaid P&T meeting. D. Darger seconded. Motion passed unanimously and the meeting was adjourned.